1,696 IDEXX Laboratories, Inc. $IDXX Shares Sold by Geneva Capital Management LLC

Geneva Capital Management LLC decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 4.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 38,546 shares of the company’s stock after selling 1,696 shares during the quarter. Geneva Capital Management LLC’s holdings in IDEXX Laboratories were worth $20,128,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Hantz Financial Services Inc. increased its position in IDEXX Laboratories by 22.5% in the third quarter. Hantz Financial Services Inc. now owns 11,305 shares of the company’s stock worth $5,903,000 after purchasing an additional 2,074 shares during the last quarter. Ground Swell Capital LLC purchased a new stake in IDEXX Laboratories during the third quarter valued at $209,000. Phoenix Financial Ltd. increased its holdings in shares of IDEXX Laboratories by 51.8% in the 3rd quarter. Phoenix Financial Ltd. now owns 1,509 shares of the company’s stock worth $789,000 after buying an additional 515 shares during the last quarter. Diversified Trust Co increased its holdings in shares of IDEXX Laboratories by 41.1% in the 3rd quarter. Diversified Trust Co now owns 1,825 shares of the company’s stock worth $953,000 after buying an additional 532 shares during the last quarter. Finally, Aberdeen Group plc raised its position in shares of IDEXX Laboratories by 1,131.8% during the 3rd quarter. Aberdeen Group plc now owns 92,508 shares of the company’s stock valued at $48,307,000 after buying an additional 84,998 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. BTIG Research dropped coverage on shares of IDEXX Laboratories in a report on Friday, October 30th. They issued a “buy” rating for the company. JPMorgan Chase & Co. reduced their price objective on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research note on Friday, October 16th. UBS Group upped their price objective on IDEXX Laboratories from $627.00 to $700.00 and gave the company a “neutral” rating in a research report on Tuesday, November 3rd. Barclays lowered their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Seven analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $717.27.

Get Our Latest Analysis on IDXX

IDEXX Laboratories Stock Performance

IDXX opened at $704.23 on Monday. The firm has a market cap of $55.49 billion, a price-to-earnings ratio of 47.49 and a beta of 1.55. The company has a current ratio of 1.19, a quick ratio of 0.88 and a debt-to-equity ratio of 0.16. IDEXX Laboratories, Inc. has a 12 month low of $500.61 and a 12 month high of $769.98. The stock has a fifty day moving average price of $562.41 and a 200-day moving average price of $573.52.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter last year, the company earned $3.22 earnings per share. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Daniel M. Junius sold 1,200 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $704.07, for a total transaction of $844,884.00. Following the completion of the transaction, the director directly owned 2,361 shares of the company’s stock, valued at approximately $1,662,309.27. This trade represents a 33.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael Lane sold 3,979 shares of the business’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $688.64, for a total transaction of $2,740,098.56. Following the transaction, the executive vice president owned 4,076 shares of the company’s stock, valued at $2,806,896.64. This represents a 49.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 41,428 shares of company stock valued at $28,567,934. 0.79% of the stock is currently owned by company insiders.

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

Further Reading

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.